The augmented PTCH1 expression would reduce Hh pathway activity, reducing the quiescence of CML stem cells; this effect would sensitize this cell population to imatinib treatment. Here, PTCH1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.